TEST BANK FOR ABRAMS’ CLINICAL DRUG THERAPY
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
Abrams' Clinical Drug Therapy: Rationales For
Nursing Practice Thirteenth, Edition By Geralyn
Frandsen Edd Rn (Author), Sandra
Pennington (Author) Latest Edition 2026
,TEST BANK FOR ABRAMS’ CLINICAL DRUG THERAPY
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
test bank for abrams’ clinical drug therapy rationales for nursing practice 13th edition
geralyn frandsen - isbn/issn 9781975136130
table of content
1. section 1 the conceptual framework of pharmacology
2. chapter 1 the foundation of pharmacology: quality and safety
3. chapter 2 basic concepts and processes
4. chapter 3 medication administration and the nursing process of drug therapy
5. section 2 drug therapy throughout the lifespan
6. chapter 4 pharmacology and the care of infants and pediatric patients medication administration in pediatrics
7. chapter 5 pharmacology and the care of adults and geriatric patients
8. chapter 6 pharmacology and the care of pregnant or lactating woman
9. chapter 7 pharmacology and women’s health
10. chapter 8 pharmacology and men’s health
11. section 3 drugs affecting the hematopoietic and immune systems
12. chapter 9 drug therapy for coagulation disorders
13. chapter 10 drug therapy for dyslipidemia
14. chapter 11 drug therapy for hematopoietic disorders
15. chapter 12 drug therapy: immunizations
16. chapter 13 drug therapy to decrease immunity
17. chapter 14 drug therapy for the treatment of cancer
18. section 4 drugs affecting inflammation and infection
19. chapter 15 inflammation, infection, and the use of antimicrobial agents
20. chapter 16 drug therapy to decrease pain, fever, and inflammation
21. chapter 17 drug therapy with corticosteroids
22. chapter 18 drug therapy with beta-lactam antibacterial agents
23. chapter 19 drug therapy with aminoglycosides and fluoroquinolones
24. chapter 20 drug therapy with tetracyclines, sulfonamides, and urinary antiseptics
25. chapter 21 drug therapy with macrolides and miscellaneous anti-infective agents
26. chapter 22 drug therapy for tuberculosis and mycobacterium avium complex disease
27. chapter 23 drug therapy for viral infections
28. chapter 24 drug therapy for fungal infections
29. chapter 25 drug therapy for parasitic infections
30. section 5 drugs affecting the cardiovascular system
31. chapter 26 drug therapy for hypertension
32. chapter 27 drug therapy for dysrhythmias
33. chapter 28 drug therapy for coronary heart disease
34. chapter 29 drug therapy for shock and hypotension
35. chapter 30 drug therapy for heart failure
36. section 6 drugs affecting the respiratory system
37. chapter 31 drug therapy for nasal congestion and cough
38. chapter 32 drug therapy to decrease histamine effects and allergic response
39. chapter 33 drug therapy for asthma and bronchoconstriction
40. section 7 drugs affecting the renal and digestive systems
41. chapter 34 drug therapy for fluid volume excess
,TEST BANK FOR ABRAMS’ CLINICAL DRUG THERAPY
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
42. chapter 35 nutritional support products, vitamins, and mineral supplements
43. chapter 36 drug therapy for weight management
44. chapter 37 drug therapy for peptic ulcer disease and hyperacidity
45. chapter 38 drug therapy for nausea and vomiting
46. chapter 39 drug therapy for constipation and elimination problems
47. chapter 40 drug therapy for diarrhea
48. section 8 drugs affecting the endocrine system
49. chapter 41 drug therapy for diabetes mellitus
50. chapter 42 drug therapy for hyperthyroidism and hypothyroidism
51. chapter 43 drug therapy for pituitary and hypothalamic dysfunction
52. chapter 44 drug therapy to regulate calcium and bone metabolism
53. chapter 45 drug therapy for addison’s disease and cushing’s disease
54. section 9 drugs affecting the autonomic and central nervous system
55. chapter 46 physiology of the autonomic and central nervous systems and indications for the use of drug
therapy
56. chapter 47 drug therapy for myasthenia gravis, alzheimer’s disease, and urinary retention
57. chapter 48 drug therapy for parkinson’s disease, urinary spasticity, and disorders requiring anticholinergic
drug therapy
58. chapter 49 drug therapy with opioids
59. chapter 50 drug therapy with local anesthetics
60. chapter 51 drug therapy with general anesthetics
61. chapter 52 drug therapy for migraines and other headaches
62. chapter 53 drug therapy for seizure disorders and spasticity
63. chapter 54 drug therapy for anxiety and insomnia
64. chapter 55 drug therapy for depression and mood stabilization
65. chapter 56 drug therapy for psychotic disorders
66. chapter 57 drug therapy for attention deficit hyperactivity disorder and narcolepsy
67. chapter 58 drug therapy for substance abuse disorders
68. section 10 drugs affecting the eye, ear, and skin
69. chapter 59 drug therapy for disorders of the eye
70. chapter 60 drug therapy for disorders of the ear
71. chapter 61 drug therapy for disorders of the skin
, [DOCUMENT TITLE]
GRADESBOOST.COM
chapter 1, the foundation of pharmacology: quality and safety
1. a woman diagnosed with obsessive–
compulsive disorder has been prescribed oral paroxetine hydrochloride. what is
the expected effect for this prescription?
A. curative effect on symptoms
B. systemic effect on symptoms
C. local effect on symptoms
D. parenteral effect on symptoms
ANS: b
rationale: drugs that produce systemic effects are taken into the body, circulated through
G R A D E S B O O S T . C O M
the bloodstream to their sites of action in various body tissues, and eventually eliminated f
rom the body. curative agents are given to cure a disease process. in this case, paroxetine
hydrochloride will control the symptoms but not cure the disorder. drugs with local effects
, such as sunscreen and local anesthetics, act mainly at the site of application. paroxetine h
ydrochloride is not administered parenterally. parenteral agents are administered subcutane
ously, intramuscularly, or intravenously.
pts: 1 ref: p. 3, introduction obj: 1
nat: client needs: physiological integrity: pharmacological and parenteral therapie s
top: chapter: 1: the foundation of pharmacology: quality and safety
key: integrated process: nursing process
blm: cognitive level: understand not: multiple choice
2. a client has been prescribed an antibiotic. this medication is a naturally occurring
substance that has been chegmricaaldlyem
sobdoifoiesd.tw
.hcaotwmi s another name for this type of me
dication?
A. synthetic drug
B. semisynthetic drug
C. biotechnology drug
D. prototype drug
ANS: b
rationale: semisynthetic drugs (e.g., many antibiotics) are naturally occurring substances t
hat have been chemically modified. synthetic drugs are more standardized in their chemica
l characteristics, more consistent in their effects, and less likely to produce allergic reactio
ns. biotechnology drugs involve manipulating dna and rna and recombining genes into
hybrid molecules that can be inserted into living organisms. prototype drugs are the first
drug of a particular group to be developed.
pts: 1 ref: p. 3, drug sources obj: 1
nat: client needs: physiological integrity: pharmacological and parenteral therapie s
top: chapter: 1: the foundation of pharmacology: quality and safety
key: integrated process: nursing process
blm: cognitive level: understand not: multiple choice
3. which classification applies to morphine?
GRADESBOOST.COM #1 TEST BANKS WEBSITE
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
Abrams' Clinical Drug Therapy: Rationales For
Nursing Practice Thirteenth, Edition By Geralyn
Frandsen Edd Rn (Author), Sandra
Pennington (Author) Latest Edition 2026
,TEST BANK FOR ABRAMS’ CLINICAL DRUG THERAPY
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
test bank for abrams’ clinical drug therapy rationales for nursing practice 13th edition
geralyn frandsen - isbn/issn 9781975136130
table of content
1. section 1 the conceptual framework of pharmacology
2. chapter 1 the foundation of pharmacology: quality and safety
3. chapter 2 basic concepts and processes
4. chapter 3 medication administration and the nursing process of drug therapy
5. section 2 drug therapy throughout the lifespan
6. chapter 4 pharmacology and the care of infants and pediatric patients medication administration in pediatrics
7. chapter 5 pharmacology and the care of adults and geriatric patients
8. chapter 6 pharmacology and the care of pregnant or lactating woman
9. chapter 7 pharmacology and women’s health
10. chapter 8 pharmacology and men’s health
11. section 3 drugs affecting the hematopoietic and immune systems
12. chapter 9 drug therapy for coagulation disorders
13. chapter 10 drug therapy for dyslipidemia
14. chapter 11 drug therapy for hematopoietic disorders
15. chapter 12 drug therapy: immunizations
16. chapter 13 drug therapy to decrease immunity
17. chapter 14 drug therapy for the treatment of cancer
18. section 4 drugs affecting inflammation and infection
19. chapter 15 inflammation, infection, and the use of antimicrobial agents
20. chapter 16 drug therapy to decrease pain, fever, and inflammation
21. chapter 17 drug therapy with corticosteroids
22. chapter 18 drug therapy with beta-lactam antibacterial agents
23. chapter 19 drug therapy with aminoglycosides and fluoroquinolones
24. chapter 20 drug therapy with tetracyclines, sulfonamides, and urinary antiseptics
25. chapter 21 drug therapy with macrolides and miscellaneous anti-infective agents
26. chapter 22 drug therapy for tuberculosis and mycobacterium avium complex disease
27. chapter 23 drug therapy for viral infections
28. chapter 24 drug therapy for fungal infections
29. chapter 25 drug therapy for parasitic infections
30. section 5 drugs affecting the cardiovascular system
31. chapter 26 drug therapy for hypertension
32. chapter 27 drug therapy for dysrhythmias
33. chapter 28 drug therapy for coronary heart disease
34. chapter 29 drug therapy for shock and hypotension
35. chapter 30 drug therapy for heart failure
36. section 6 drugs affecting the respiratory system
37. chapter 31 drug therapy for nasal congestion and cough
38. chapter 32 drug therapy to decrease histamine effects and allergic response
39. chapter 33 drug therapy for asthma and bronchoconstriction
40. section 7 drugs affecting the renal and digestive systems
41. chapter 34 drug therapy for fluid volume excess
,TEST BANK FOR ABRAMS’ CLINICAL DRUG THERAPY
RATIONALES FOR NURSING PRACTICE 13TH EDITION
GERALYN FRANDSEN
42. chapter 35 nutritional support products, vitamins, and mineral supplements
43. chapter 36 drug therapy for weight management
44. chapter 37 drug therapy for peptic ulcer disease and hyperacidity
45. chapter 38 drug therapy for nausea and vomiting
46. chapter 39 drug therapy for constipation and elimination problems
47. chapter 40 drug therapy for diarrhea
48. section 8 drugs affecting the endocrine system
49. chapter 41 drug therapy for diabetes mellitus
50. chapter 42 drug therapy for hyperthyroidism and hypothyroidism
51. chapter 43 drug therapy for pituitary and hypothalamic dysfunction
52. chapter 44 drug therapy to regulate calcium and bone metabolism
53. chapter 45 drug therapy for addison’s disease and cushing’s disease
54. section 9 drugs affecting the autonomic and central nervous system
55. chapter 46 physiology of the autonomic and central nervous systems and indications for the use of drug
therapy
56. chapter 47 drug therapy for myasthenia gravis, alzheimer’s disease, and urinary retention
57. chapter 48 drug therapy for parkinson’s disease, urinary spasticity, and disorders requiring anticholinergic
drug therapy
58. chapter 49 drug therapy with opioids
59. chapter 50 drug therapy with local anesthetics
60. chapter 51 drug therapy with general anesthetics
61. chapter 52 drug therapy for migraines and other headaches
62. chapter 53 drug therapy for seizure disorders and spasticity
63. chapter 54 drug therapy for anxiety and insomnia
64. chapter 55 drug therapy for depression and mood stabilization
65. chapter 56 drug therapy for psychotic disorders
66. chapter 57 drug therapy for attention deficit hyperactivity disorder and narcolepsy
67. chapter 58 drug therapy for substance abuse disorders
68. section 10 drugs affecting the eye, ear, and skin
69. chapter 59 drug therapy for disorders of the eye
70. chapter 60 drug therapy for disorders of the ear
71. chapter 61 drug therapy for disorders of the skin
, [DOCUMENT TITLE]
GRADESBOOST.COM
chapter 1, the foundation of pharmacology: quality and safety
1. a woman diagnosed with obsessive–
compulsive disorder has been prescribed oral paroxetine hydrochloride. what is
the expected effect for this prescription?
A. curative effect on symptoms
B. systemic effect on symptoms
C. local effect on symptoms
D. parenteral effect on symptoms
ANS: b
rationale: drugs that produce systemic effects are taken into the body, circulated through
G R A D E S B O O S T . C O M
the bloodstream to their sites of action in various body tissues, and eventually eliminated f
rom the body. curative agents are given to cure a disease process. in this case, paroxetine
hydrochloride will control the symptoms but not cure the disorder. drugs with local effects
, such as sunscreen and local anesthetics, act mainly at the site of application. paroxetine h
ydrochloride is not administered parenterally. parenteral agents are administered subcutane
ously, intramuscularly, or intravenously.
pts: 1 ref: p. 3, introduction obj: 1
nat: client needs: physiological integrity: pharmacological and parenteral therapie s
top: chapter: 1: the foundation of pharmacology: quality and safety
key: integrated process: nursing process
blm: cognitive level: understand not: multiple choice
2. a client has been prescribed an antibiotic. this medication is a naturally occurring
substance that has been chegmricaaldlyem
sobdoifoiesd.tw
.hcaotwmi s another name for this type of me
dication?
A. synthetic drug
B. semisynthetic drug
C. biotechnology drug
D. prototype drug
ANS: b
rationale: semisynthetic drugs (e.g., many antibiotics) are naturally occurring substances t
hat have been chemically modified. synthetic drugs are more standardized in their chemica
l characteristics, more consistent in their effects, and less likely to produce allergic reactio
ns. biotechnology drugs involve manipulating dna and rna and recombining genes into
hybrid molecules that can be inserted into living organisms. prototype drugs are the first
drug of a particular group to be developed.
pts: 1 ref: p. 3, drug sources obj: 1
nat: client needs: physiological integrity: pharmacological and parenteral therapie s
top: chapter: 1: the foundation of pharmacology: quality and safety
key: integrated process: nursing process
blm: cognitive level: understand not: multiple choice
3. which classification applies to morphine?
GRADESBOOST.COM #1 TEST BANKS WEBSITE
